Clinical Trial

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Protocol Amendment History 4 changes
critical Recruitment opened 2026-04-30
notable Trial sites expanded: 0 -> 6 locations 2026-04-30
notable Primary completion moved earlier: 2027-11-19 -> 2026-11-16 2026-04-03
minor Completion moved earlier: 2031-03-07 -> 2030-12-18 2026-04-03
Trial Details
NCT Number NCT07340138
Lead Sponsor Novartis Pharmaceuticals
Conditions Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Enrollment 6 participants
Start Date 2026-04-15
Primary Completion 2026-11-16 (estimated)
Study Completion 2030-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-16